INTRODUCTION
============

Environmental pollutants have long been considered one of the critical etiologies of the development of various pathologies such as cardiovascular, respiratory, metabolic, immunologic, and neurodegenerative diseases \[[@b1-yujm-2018-35-2-156]-[@b3-yujm-2018-35-2-156]\]. Recently, multiple accumulative studies have addressed the relationship between exposure to environmental toxicants and health outcomes.

Perfluoroalkyl compounds (PFCs) are a group of synthetic chemicals, which have been widely used since the 1950s for diverse industrial and consumer products such as carpets, clothes, non-stick cookware, food packaging and fire-foaming due to their water- and oil-repelling properties \[[@b4-yujm-2018-35-2-156]\]. Since PFCs are extremely stable and are not biodegradable, these chemicals accumulate in the ecosystem and are biomagnified via the food web \[[@b5-yujm-2018-35-2-156]-[@b7-yujm-2018-35-2-156]\]. As ubiquitous contaminants, PFCs can be detected in serum from the general population as well as industry workers, to a relatively high level compared to other environmental contaminants \[[@b8-yujm-2018-35-2-156]\]. More importantly, they are found in umbilical cord blood and breast milk \[[@b9-yujm-2018-35-2-156],[@b10-yujm-2018-35-2-156]\], suggesting a lifelong exposure to PFCs may start from fetal development. This has raised particular concerns over the potential deleterious effects of PFCs because the perinatal period is especially vulnerable to environmental toxins, which can induce developmental defects and chronic diseases. The most extensively distributed and studied PFCs are perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), and perfluorooctanoic acid (PFOA), hence most studies on potential health effects are based around these. Due to its bioaccumulative and potentially toxic properties, PFOS was added as persistent organic pollutants as an Annex B substance under the Stockholm Convention in 2009, meaning there should be 'restriction in its use' (United Nations Environment Programme 2009). Generally, the serum concentration of PFCs has been shown to be higher in developed countries. However, it is noteworthy that the serum concentration of PFOA in Korean women was about 88 ppb, which is much higher than that in the US general population (4.7-5.7 ppb) \[[@b11-yujm-2018-35-2-156]\].

With the establishment of regulation on their use, there have been extensive studies focusing on a wide range of health outcomes of PFCs. In fact, sufficient evidence has now been reported for the association between PFCs and neurotoxicity and immunosuppression.

This review aims to provide a brief introduction of PFCs and a summary of the literature comparing epidemiological and experimental evidence for the impacts of PFCs on health outcomes including neurological disorders and immune health.

Classification and physicochemical properties of PFCs
=====================================================

PFCs are aliphatic substances containing one or more carbon (C) atoms on which all hydrogen (H) atoms are replace by fluorine (F), having the C~n~F~2n+1~- moiety attached to various functional groups ([Fig. 1](#f1-yujm-2018-35-2-156){ref-type="fig"}). The major functional groups include carboxylic acid (-COOH), sulfonic acid (SO~3~H) and sulfonamides (-SO~2~NH~2~). Examples of the major PFCs are listed in [Table 1](#t1-yujm-2018-35-2-156){ref-type="table"}.

As mentioned above, the C-H covalent bond is extremely stable and resistant to chemical and thermal degradation. In addition to their water-proof and oil-proof properties, their high stability made these chemicals highly useful for application in various industrial and consumer products \[[@b4-yujm-2018-35-2-156]\]. PFCs are present in all environmental matrices, wildlife and human body even after their use was phased out. The first study demonstrating global contamination by PFCs was a report focused on the occurrence of PFOS, PFOA and other PFCs in wildlife \[[@b12-yujm-2018-35-2-156]\]. Hansen et al. \[[@b13-yujm-2018-35-2-156]\] have also reported the presence of PFOS, PFOA, and other PFCs in human blood samples obtained from several biological suppliers. Human exposure to PFCs occurs through diverse routes such as food, drinking water, breast milk, and dust \[[@b14-yujm-2018-35-2-156]\].

Many studies have shown that long-chain PFCs, i.e., C~n~F~2n+1~COOH where *n*≥7 and C~n~F~2n+1~-SO~3~H where *n*≥6, which include PFOA and PFOS, are more bioaccumulative and have longer elimination half-lives than short-chain PFCs \[[@b15-yujm-2018-35-2-156]-[@b18-yujm-2018-35-2-156]\]. Therefore, PFOA and PFOS have received particular attention from the global regulatory community and scientific groups. The global concern over the potential environmental and health impact of long-chain PFCs has led to the phase-out of production of PFOA and PFOS by their major manufacturer (the 3M Company) in 2000, and has facilitated regulatory initiatives to reduce the environmental release of these PFCs in many countries. PFHxS, the six carbon congener (C6) is generally considered to be less toxic than PFOS (C8) and has therefore replaced PFOS in many industrial applications. Although the biological effects of PFHxS are less studied than those of other PFCs, PFHxS is one of three major PFCs found in human blood and has physicochemical properties similar to PFOS \[[@b19-yujm-2018-35-2-156]\]. Importantly, the serum level of PFHxS in children has been reported to be higher than in adults \[[@b20-yujm-2018-35-2-156]-[@b22-yujm-2018-35-2-156]\].

The potential health impacts of PFCs
====================================

The global attention to PFCs has led to multiple epidemiological and experimental studies to elucidate their toxicological impacts, in addition to the regulations and agreements between related organizations to restrict their use. The Mid-Ohio Valley C8 Cohort Study during 2005-2013 conducted epidemiological investigations on exposure and health outcomes in communities of the Mid-Ohio Valley, an area which has been contaminated with PFOA(or C8) from the Washington Works plant in Parkersburg, West Virginia since the 1950s. The conclusions of the study are published in multiple scientific papers which report probable links between exposure and various health conditions, such as high cholesterol, thyroid disease, ulcerative colitis, pregnancy hypertension, and cancers (testicular and kidney) \[[@b23-yujm-2018-35-2-156]-[@b26-yujm-2018-35-2-156]\]. In 2013, the southwest of the Veneto Region, Italy, was known to be affected by massive PFC contamination of tap water, as well as ground and surface water. Comprehensive studies on biomonitoring and risk assessment have been conducted as a result, and studies on continuous biomonitoring and long-term health outcomes are still ongoing \[[@b27-yujm-2018-35-2-156]\]. Very recently, it has been announced that PFCs, in particular PFHxS, are detected at a high concentration in the tap water of the Daegu and Busan regions in Korea. This is due to contamination of the Nakdong River, a major source of drinking water in these regions. Epidemiological studies involving the populations of these areas are therefore warranted in the near future.

1. Neurodevelopmental and neurodegenerative impacts
---------------------------------------------------

Neurodevelopment involves complex and dynamic processes. The perinatal period, which involves the brain growth spurt (BGS), is exquisitely vulnerable to environmental stimuli and the impairment of neurodevelopment during this period can induce serious neurological disorders affecting life-long health. Considering the reports that PFCs are found in cord blood and breast milk \[[@b9-yujm-2018-35-2-156],[@b10-yujm-2018-35-2-156]\], the potential of PFCs to induce neurotoxicity have drawn both scientific and public concerns. To examine the association between PFCs and neurological outcomes, a large number of studies have been conducted using human and animal subjects.

Studies examining neurodevelopmental markers have generally reported no association with PFCs \[[@b28-yujm-2018-35-2-156]-[@b35-yujm-2018-35-2-156]\], however some studies have presented positive associations. Fei et al. \[[@b28-yujm-2018-35-2-156]\] found that the PFOS level measured in maternal blood samples in early pregnancy was inversely correlated with the ability of the child to sit without support at 18 months of age. However, no association was found between maternal PFOA and PFOS levels and behavioral and motor coordination at 7 years of age in the same cohort \[[@b36-yujm-2018-35-2-156]\]. In a cohort in Cincinnati, increased PFOS in maternal blood was positively associated with executive function deficits at 5-8 years of age \[[@b37-yujm-2018-35-2-156]\]. Furthermore, Harris et al. \[[@b38-yujm-2018-35-2-156]\] reported an inverse association between prenatal and childhood exposure to PFCs and childhood visual motor abilities.

Many different cohort studies have reported a positive association between prenatal exposure to PFCs and attention deficit hyperactivity disorder (ADHD) or related behavioral problems. In the Taiwan Birth Panel Study and the Taiwan Early-Life Cohort, the level of perfluorononanoic acid (PFNA), but not PFOA and PFOS in umbilical cord blood was associated with ADHD at 7 years of age \[[@b39-yujm-2018-35-2-156]\]. Similarly, positive associations have been reported between serum PFOS and PFHxS and ADHD in children \[[@b35-yujm-2018-35-2-156]\], maternal PFOA and increased hyperactivity and behavioral problems \[[@b40-yujm-2018-35-2-156]\], and maternal PFOA and ADHD\[[@b41-yujm-2018-35-2-156]\]. In contrast, Ode et al. \[[@b42-yujm-2018-35-2-156]\] reported no association between prenatal exposure to PFCs and ADHD in a Swedish cohort.

As well as potentially causing neurodevelopmental defects in children, early exposure to environmental toxicants could be a critical causal factor for increased risk of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases in later life \[[@b43-yujm-2018-35-2-156]-[@b45-yujm-2018-35-2-156]\]. Very recently, an epidemiological study conducted in Italy has reported a higher level of mortality by Alzheimer's disease in areas contaminated with PFCs in drinking water compared with uncontaminated areas \[[@b46-yujm-2018-35-2-156]\].

In addition to epidemiological studies, experimental animal studies have provided additional evidence of the life-long effects of PFC-induced neurological damages. For example, neonatal exposure to PFOS and PFOA resulted in alteration of the expression of critical neuroproteins in the developing brain and neurobehavioral defects manifested as changes in spontaneous behavior and habitation in adult mice \[[@b47-yujm-2018-35-2-156],[@b48-yujm-2018-35-2-156]\]. Similar results were observed with neonatal exposure to PFHxS \[[@b49-yujm-2018-35-2-156],[@b50-yujm-2018-35-2-156]\]. Although the molecular mechanisms responsible for the neurotoxic effects caused by PFCs are not completely understood, apoptosis of neuronal cells during the BGS period is considered as a critical causal factor for the disturbance of neurobehavioral function, which can manifest either in childhood or in adulthood \[[@b51-yujm-2018-35-2-156]\]. We have recently reported that PFOS induced apoptosis of cerebellar granule cells via reactive oxygen species-dependent protein kinase C and extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathways \[[@b52-yujm-2018-35-2-156],[@b53-yujm-2018-35-2-156]\]. Similarly, PFHxS increased neuronal cell apoptosis via N-methyl-D-aspartate-mediated ERK1/2 and AMP-activated protein kinase pathways \[[@b54-yujm-2018-35-2-156]-[@b56-yujm-2018-35-2-156]\]. A summary of epidemiological and laboratory experimental studies related to the neurological impact of PFCs are presented in [Table 2](#t2-yujm-2018-35-2-156){ref-type="table"}.

Despite several epidemiological studies reporting the positive association of PFCs with neurological disorders such as ADHD and Alzheimer's disease, as well as experimental animal studies reporting the underlying mechanism for the neurotoxicity of PFCs, the evidence for the association of PFCs with neurodevelopmental defects are still inconsistent. Therefore, further studies are needed for solid conclusions on this causal relationship.

2. Immunoregulatory impacts
---------------------------

The perinatal period is a critical time for immune system development and exposure to environmental pollutants during this period can adversely affect immune functions including antibody production and increase the development of allergic phenotypes \[[@b57-yujm-2018-35-2-156]-[@b61-yujm-2018-35-2-156]\]. Dysregulation of immune responses may increase the risk of infectious diseases, hypersensitivity disorders, and even death. Therefore, elucidation of a possible relationship between exposure to environmental contaminants and immunological diseases is paramount.

Several animal studies have provided evidence for immunotoxic effects of PFCs. In adult B6C3F1 mice exposed for 28 days to PFOS at serum concentrations reported in general population and occupationally exposed humans, the immune response, possibly involving B-cell dependent immunoglobulin M(IgM) production, was suppressed \[[@b62-yujm-2018-35-2-156]\]. Furthermore, a study by Guruge et al. \[[@b63-yujm-2018-35-2-156]\] reported that gavage exposure of female B6C3F1 mice to PFOS (0.025 and 0.05mg/kg body weight/day) for 21 days increased mortality after infection with influenza A virus in a dose-dependent manner. Recently, a growing number of epidemiological studies have also demonstrated an association of prenatal and postnatal exposure to PFCs with immunotoxicity. In a birth cohort of the National Hospital in the Faroe Islands, the serum levels of PFOS and PFOA at age 5 were negatively associated with diphtheria antibody concentration at age 7 \[[@b64-yujm-2018-35-2-156]\]. Consistent results were observed at age 13 in the same cohort group \[[@b65-yujm-2018-35-2-156]\]. In accordance with the immunosuppressive effects of PFCs, prenatal exposure has been inversely correlated with the level of rubella antibody and positively correlated with the incidence of the common cold at age 3, as measured in the Norwegian Mother and Child cohort \[[@b66-yujm-2018-35-2-156]\]. In a hospital-based cohort of Hokkaido, Japan, prenatal exposure to PFOS and PFHxS increased the incidence of infectious diseases including otitis media, pneumonia, respiratory syncytial virus infection and varicella up to 4 years of age \[[@b67-yujm-2018-35-2-156]\]. Timmermann et al. \[[@b68-yujm-2018-35-2-156]\] reported that the serum levels of PFHxS, PFOA, PFOS, PFNA and perfluorodecanoic acid at 5 years of age were associated with increased risk of asthma or allergic diseases in the measles, mumps, and rubella (MMR)-unvaccinated group but not in the MMR-vaccinated group. In this study, prenatal exposure to PFCs showed no association with asthma or allergic diseases. The immunosuppressive effect of PFCs has also been observed in adult individuals. Kielsen et al. \[[@b69-yujm-2018-35-2-156]\] reported that the serum PFC level in adults was negatively associated with the rate of increase in antibody responses following booster vaccination with diphtheria and tetanus. Although there are few studies on the association of PFC exposure with allergic responses, Buser and Scinicariello \[[@b70-yujm-2018-35-2-156]\] reported a positive correlation between serum levels of PFCs including PFOA, PFOS and PFHxS and self-reported food allergies in adolescents. We recently examined the effects of PFOS on the activation of mast cells, a specialized cell type involved in IgE-antigen mediated allergic responses. PFOS significantly increased activation of mast cells as measured by degranulation, production of the eicosanoids PGD~2~ and LTC~4~, and calcium influx \[[@b71-yujm-2018-35-2-156]\].

Although there are fewer studies on immunomodulatory effects than those on other health outcomes elicited by PFCs, recent epidemiological studies have provided some solid evidence for immunosuppressive effects on pediatric vaccination and other immune-related responses in both childhood and adulthood. A summary of epidemiological and laboratory experimental studies relating to the immunomodulatory effects of PFCs are presented in [Table 3](#t3-yujm-2018-35-2-156){ref-type="table"}.

CONCLUSION
==========

This review summarizes the neurotoxicological and immunotoxicological impacts of PFCs from peer-reviewed studies. During the last decade, these has been an impressive increase in studies examining the association of PFCs with health risk potential. Although this review does not cover all aspects of health outcomes caused by PFCs, neurological and immunological disorders are the most concerning potential health outcomes resulting from exposure to diverse environmental toxicants including PFCs. The epidemiological and toxicological studies provide evidence for positive association of PFCs, mostly PFOA, PFOS, and PFHxS with ADHD. One study also suggests the possible relationship between exposure to PFCs and Alzheimer's disease. Several animal and in vitro studies provide evidence supporting the neurotoxic effects of PFCs and have presented molecular mechanisms responsible for neuronal cell apoptosis. To date, there have been limited studies on the effects of PFCs on immunological responses. However, several epidemiological studies have reported that serum levels of PFCs are inversely related with the immune response to vaccination both in childhood and adulthood. In addition, immunosuppressive effects of PFCs have been consistently observed in animal studies. Although positive associations with asthma and other allergic diseases have been reported, more studies are needed to lead a concrete conclusion.

Since PFOS, PFOA, and PFHxS are the PFCs most highly detected in humans, these are the focus of most current studies on the health effects of PFCs. Considering the longer chain PFCs have longer elimination half-lives, more investigations are needed to gain toxicological information on the longer-chain PFCs and to identify the underlying mechanisms of action of novel PFCs. In addition, many studies have discussed their health outcomes as individual compounds, whereas PFCs can be mixed with diverse contaminants in the environment. The composition of these contaminant mixtures can change over time and also vary depending on location. The chemicals within such mixtures may share a common pathway or may have disparate pathways in terms of their mechanisms of action, potentially leading to potentiated effects or unexpected outcomes. Therefore, in addition to studies on the action of PFCs as individual chemicals, more research on their impact as complex mixtures is needed for practical application in the future.
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###### 

Classification and chemical formula of major PFC congeners

  Classification                   C~n~F~2n+1~R, where R=   Examples              
  -------------------------------- ------------------------ --------------------- -------
  Perfluoroalkyl carboxylic acid   -COOH                    C~7~F~15~COOH         PFOA
                                                            C~8~F~17~COOH         PFNA
  Perfluoroalkane sulfonic acid    -SO~3~H                  C~6~F~13~SO~3~H       PFHxS
                                                            C~8~F~17~SO~3~H       PFOS
  Perfluoroalkane sulfonamide      -SO~2~NH~2~              C~8~F~17~SO~2~NH~2~   FOSA

PFC, perfluoroalkyl compounds; PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; PFOS, perfluorooctane sulfonic acid; FOSA, perfluorooctane sulfonamide.

###### 

Summary of PFCs and neurodevelopmental and neurodegenerative impacts

  Study group                                                 Sample                         PFCs          Effects                                        Summary                                                                                                    References
  ----------------------------------------------------------- ------------------------------ ------------- ---------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Danish National Birth Cohort                                Maternal serum                 PFOS          Start of sit without support at age 18 mon     Negative association between PFOS and start of sit without support                                         Fei et al. \[[@b28-yujm-2018-35-2-156]\]
  A cohort in Cincinnati                                      Maternal serum                 PFOS          Executive function deficits at age 5-8 yr      Positive association between PFOS and executive function deficits                                          Vuong et al. \[[@b37-yujm-2018-35-2-156]\]
  Boston-area birth cohort                                    Maternal and childhood serum   PFCs          Visual motor abilities                         Negative association between serum PFCs and visual motor abilities                                         Harris et al. \[[@b38-yujm-2018-35-2-156]\]
  Taiwan Birth Panel Study and the Taiwan Early-Life Cohort   Cord blood                     PFNA          ADHD at age 7 yr                               Positive association between cord blood PFNA and ADHD                                                      Lien et al. \[[@b39-yujm-2018-35-2-156]\]
  Mid-Ohio Valley C8 cohort                                   Serum at age 5-18 yr           PFOS, PFHxS   Parental ADHD                                  Positive association between serum PFCs and parental report of ADHD                                        Stein and Savitz \[[@b35-yujm-2018-35-2-156]\]
  INUENDO cohort                                              Serum of child                 PFOA          Hyperactivity and behavioral problems          Positive association between serum PFOA and hyperactivity and behavioral problems                          Hoyer et al. \[[@b40-yujm-2018-35-2-156]\]
  Danish National Birth Cohort                                Maternal serum                 PFOA          ADHD                                           Positive association between serum PFOA and ADHD                                                           Liew et al. \[[@b41-yujm-2018-35-2-156]\]
  A cohort in Italy including Veneto Region                   Drinking water                 PFCs          Mortality caused by Alzheimer、disease         Positive association between level of PFCs in drinking water and mortality caused by Alzheimer's disease   Mastrantonio et al. \[[@b46-yujm-2018-35-2-156]\]
  Mice                                                        Serum                          PFOS, PFOA    Spontaneous behavior and habitation in adult   Positive association between serum PFOS and PFOA and spontaneous behavior and habitation in adult          Johansson et al. \[[@b48-yujm-2018-35-2-156]\]
  Mice                                                        Serum                          PFOS, PFOA    Neuroprotein expression in developing brain    Positive association between serum PFOS and PFOA and alteration of neuroprotein expression                 Johansson et al. \[[@b47-yujm-2018-35-2-156]\]
  Mice                                                        Serum                          PFHxS         Cognitive disturbance in adult                 Positive association between serum PFHxS and cognitive disturbance in adult                                Viberg et al. \[[@b50-yujm-2018-35-2-156]\]
  Mice                                                        Serum                          PFHxS         Neuroprotein expression in developing brain    Positive association between serum PFHxS and alteration of neuroprotein expression                         Lee and Viberg \[[@b49-yujm-2018-35-2-156]\]
  Cerebellar granule cell                                                                    PFOS          Apoptosis                                      PFOS increases apoptosis via ROS-PKC pathway                                                               Lee et al. \[[@b52-yujm-2018-35-2-156]\]
  Cerebellar granule cell                                                                    PFOS          Apoptosis                                      PFOS increases apoptosis via ERK1/2 pathway                                                                Lee et al. \[[@b53-yujm-2018-35-2-156]\]
  Cerebellar granule cell                                                                    PFHxS         Apoptosis                                      PFHxS increases apoptosis via ERK1/2 pathway                                                               Lee et al. \[[@b54-yujm-2018-35-2-156]\]
  PC12 cells                                                                                 PFHxS         Apoptosis                                      PFHxS increases apoptosis via NMDA-ERK1/2 pathway                                                          Lee et al. \[[@b55-yujm-2018-35-2-156]\]
  PC12 cells                                                                                 PFHxS         Apoptosis                                      PFHxS increases apoptosis via AMPK pathway                                                                 Lee et al. \[[@b56-yujm-2018-35-2-156]\]

PFC, perfluoroalkyl compounds; PFOS, perfluorooctane sulfonic acid; PFNA, perfluorononanoic acid; ADHD, attention deficit hyperactivity disorder; PFHxS, perfluorohexane sulfonic acid; PFOA, perfluorooctanoic acid; ROS, reactive oxygen species; PKC, protein kinase C; ERK1/2, extracellular signal-regulated kinase 1/2; NMDA, N-methyl-D-aspartate; AMPK, AMP-activated protein kinase.

###### 

Summary of PFCs and immunoregulatory impacts

  Study model                                                  Sample                  PFCs                            Effects                                                                        Summary                                                                                     References
  ------------------------------------------------------------ ----------------------- ------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- -------------------------------------------------------
  Birth cohort of the National Hospital in the Faroe Islands   Serum at age 5 yr       PFOS, PFOA                      Diphtheria antibody at age 7 yr                                                Negative association between PFOS and PFOA and antibody production                          Grandjean et al. \[[@b64-yujm-2018-35-2-156]\]
  Birth cohort of the National Hospital in the Faroe Islands   Serum at age 5 yr       PFOS, PFOA                      Diphtheria antibody at age 13 yr                                               Negative association between PFOS and PFOA and antibody production                          Grandjean et al. \[[@b65-yujm-2018-35-2-156]\]
  Norwegian Mother and Child cohort                            Maternal serum          PFCs                            Rubella antibody at age 3 yr                                                   Negative association between maternal serum PFCs and antibody concentration                 Granum et al. \[[@b66-yujm-2018-35-2-156]\]
  Hospital-based cohort of Hokkaido                            Maternal serum          PFOS, PFHxS                     Otitis media, pneumonia, respiratory Syncytial virus infection and varicella   Positive association between maternal serum PFOS and PFHxS infectious diseases              Goudarzi et al. \[[@b67-yujm-2018-35-2-156]\]
  A cohort of Faroese children                                 Serum at age 5 yr       PFHxS, PFOA, PFOS, PFNA, PFDA   Asthma or allergic diseases                                                    Positive association between serum PFCs and increased risk of asthma or allergic diseases   Timmermann et al. \[[@b68-yujm-2018-35-2-156]\]
  12 healthy adult volunteers                                  Serum of adult          PFCs                            Booster vaccination with diphtheria and tetanus                                Negative association between serum PFCs and rate of increase in antibody responses          Kielsen et al. \[[@b69-yujm-2018-35-2-156]\]
  NHANES in U.S.                                               Serum at age 12-19 yr   PFOS, PFOA, PFHxS               Food allergy                                                                   Positive association between serum PFCs and self-reported food allergy                      Buser and Scinicariello \[[@b70-yujm-2018-35-2-156]\]
  Adult B6C3F1 mice                                            Serum                   PFOS                            IgM production                                                                 Negative association between serum PFOS and B-cell mediated IgM production                  Peden-Adams et al. \[[@b62-yujm-2018-35-2-156]\]
  Female B6C3F1 mice                                           Serum                   PFOS                            Mortality after influenza A infection                                          Positive association between serum PFOS and mortality after influenza A infection           Guruge et al. \[[@b63-yujm-2018-35-2-156]\]

PFC, perfluoroalkyl compounds; PFOS, perfluorooctane sulfonic acid; PFOA, perfluorooctanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFDA, perfluorodecanoic acid; NHANES, National Health and Nutrition Examination Survey; IgM, immunoglobulin M.
